NCT01961843View on ClinicalTrials.gov

Abiraterone Acetate for Castrate Resistant Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone

Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.

DRUG

Prednisone

Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER